{
  "schemaVersion": 1,
  "id": "research-310",
  "slug": "310-what-triumph-1-established-about-average-weight-change",
  "title": "What TRIUMPH-1 established about average weight change",
  "catalogLabel": "RETA GLP-3",
  "productCollection": "https://heritagebiolabs.com/research-library/products/reta-glp-3",
  "productHandles": [
    "reta-glp-3-689",
    "reta-glp-3-690",
    "reta-glp-3-705",
    "reta-glp-3-706"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/reta-glp-3-689",
    "https://heritagebiolabs.com/product/reta-glp-3-690",
    "https://heritagebiolabs.com/product/reta-glp-3-705",
    "https://heritagebiolabs.com/product/reta-glp-3-706"
  ],
  "readingFocus": "Study findings",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 381,
  "sourceYears": [
    2025,
    2026
  ],
  "paragraphs": [
    "A peptide is a short amino-acid chain joined by peptide bonds. Some engineered peptides can act at several hormone receptors. Retatrutide activates the GIP, GLP-1 and glucagon receptors, the three targets behind its description as a triple agonist. The “GLP-3” catalog wording refers to the entry, while the scientific names identify the receptors studied. In TRIUMPH-1, investigators asked how retatrutide affected weight in adults with obesity who did not have diabetes. [1]",
    "TRIUMPH-1 was a phase 3 randomized, double-blind, placebo-controlled study. A total of 2,339 adults underwent randomization. The investigators studied several groups receiving retatrutide and a group receiving placebo, with the main weight comparison at 80 weeks. The trial also contained defined subgroups with knee osteoarthritis or obstructive sleep apnea and studied outcomes specific to those conditions. The weight results describe the broader trial group. The subgroup results concern the participants who met the additional criteria. [1]",
    "The estimated average percentage weight changes were −17.6%, −23.7% and −25.0% in the three retatrutide groups, compared with −3.9% in the placebo group. The principal comparisons involved the two higher study groups. The authors used an analysis intended to reflect assignment to treatment even when events such as discontinuation occurred. The values are estimates for study groups, with variation among individuals. They do not describe the result for each person or show whether weight continued to change after week 80. [1]",
    "This was a controlled comparison with placebo. It gives a basis for estimating differences between the study groups under the trial’s procedures. It does not directly compare retatrutide with another active obesity medicine in the same population. When reading a different trial, differences in eligibility, follow-up, treatment support and statistical analysis can make the percentages difficult to compare without a head-to-head study. [1]",
    "A phase 3 result is one component of the evidence regulators can review. It reports what happened with a defined investigational product under a specified protocol. The FDA has described retatrutide as lacking an approved product. The magnitude of the group-level weight change does not establish the identity or composition of material sold elsewhere under the same name. That is a separate question of product testing and regulatory review. The distinction keeps the result tied to the trial material and the participants for whom it was measured. [1, 2]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Ania M. Jastreboff et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. The New England Journal of Medicine (publication 2026-09-29).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42814954/"
    },
    {
      "number": 2,
      "citation": "U.S. Food and Drug Administration. Darmerica, LLC - 716152 - 12/08/2025. FDA warning letter (publication 2025-12-08).",
      "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/310-what-triumph-1-established-about-average-weight-change",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/310-what-triumph-1-established-about-average-weight-change.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/310-what-triumph-1-established-about-average-weight-change.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 062 - PT-141 and RETA GLP-3.docx",
    "sourceArticleNumber": 310,
    "contentSha256": "afbe6ee42e41c1f613318d9ff32ca8831a621a41b3c8fa3df3422cdc03c453b4",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
